Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.

ABSTRACT:

SUBMITTER: Sharman JP 

PROVIDER: S-EPMC8979808 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature